Abstract
Aims: Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), has not reduced risk of cardiovascular disease outcomes......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
